Skip to content

Reducing Rheumatoid Arthritis symptoms with Mustadi ghan vati

CLINICAL EVALUATION OF MUSTADI GHANVATI IN AMAVATA (RHEUMATOID ARTHRITIS) - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/074536
Enrollment
30
Registered
2024-10-01
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M069- Rheumatoid arthritis, unspecified

Interventions

None listed

Sponsors

Diksha Thakur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient willing to participate in the trial and sign the consent form. 2. Patients of Rheumatoid arthritis with features mentioned in subjective parameters. 3. The patients between the age group of 20 to 50 years of age. 4. Patients having classical features of Amavata like Angamarda, Aruchi,Trishna, Hrillasa, Alasya, Gaurava, Jwara, Shoola, Shotha. 5..Patients must fulfill the criteria for rheumatoid arthritis outlined by the 2010 ACR (American College of Rheumatology) and EULAR (European League Against Rheumatism).

Exclusion criteria

Exclusion criteria: 1.Patient not willing for trial. 2. Patient below the age of 20 years and above 50 years. 3.Patients having Severe crippling bone deformity 4.Patients having another type of arthropathy such as Gout, Ankylosing spondylitis etc. 5. Juvenile rheumatoid arthritis, Severely deformed joints, with genetic and endocrinal disorder, or any other chronic illness. 6. Patients taking antibiotic therapy for any systemic illness within 2 months, Pregnant women and lactating mother. 7. Any other patient considered unfit for inclusion in trial after investigation.

Design outcomes

Primary

MeasureTime frame
RELIEF IN SUBJECTIVE PARAMETERS :- 1.PAIN 2.SWELLING 3.STIFFNESS 4.TENDERNESS 5.GENERAL SYMPTOMSTimepoint: First follow up- after 15 days of first trial Second follow up - 15 days after first follow up. Third follow up- 15 days after second follow up

Secondary

MeasureTime frame
RELIEF IN OBJECTIVE PARAMETERS :- 1.JOINT INVOLVEMENT 2.SEROLOGY (RA FACTOR ) 3.ACUTE PHASE REACTANTTimepoint: ASSESSMENT WILL BE DONE ON 0 DAY AND 45 DAYS .

Countries

India

Contacts

Public ContactDiksha Thakur

Quadra Institute Of Ayurveda and Hospital NH58 Roorkee - Haridwar road near montfort school Roorkee

drrajnikant83@gmail.com8557076393

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026